XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
FAIR VALUE MEASUREMENTS - Additional Information (Details)
€ in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2021
EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
In-process research and development impairment $ 0 $ 0   $ 0 $ 2,700    
Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2-              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
In-process research and development impairment     $ 2,700 0 $ 2,700    
Level 2 | Market value              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Short-term and long-term debt 20,900     20,900   $ 21,900  
Level 2 | Carrying value              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Short-term and long-term debt, carrying values 23,800     23,800   24,100  
Level 3 | Market value | Immunomedics | Fair Value, Nonrecurring              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Future royalties 1,100     1,100   1,100  
Level 3 | Carrying value | Immunomedics | Fair Value, Nonrecurring              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Future royalties $ 1,200     $ 1,200   $ 1,100  
Maximum              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Maturities of derivative instruments (in months) 18 months     18 months      
Maximum | MYR GmbH              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Liability for MYR GmbH (“MYR”) contingent consideration | €             € 300